If biopharma firms want to get the most out of continuous manufacturing, they must rethink their viral safety strategies. Existing strategies work well for batch-mode production, as hard-won experience attests. These strategies, however, are still being adapted to continuous-mode production, where protocols and equipment preferences are in flux.
{iframe}https://www.genengnews.com/insights/continuous-processing-requires-a-rethink-of-viral-strategies/{/iframe}